Cambridge, Mass. — RoslinCT said it has entered a strategic partnership with BlueRock Therapeutics to broaden access to clinical-grade pluripotent stem cell lines for cell therapy developers.
RoslinCT, a global cell therapy contract development and manufacturing organization, said the partnership will expand its pluripotent cell therapy offering to include access to BlueRock’s clinical-grade induced pluripotent stem cell lines, along with RoslinCT’s own cell lines and related services.
The companies said the expanded offering is designed to give developers a broader set of tools and support to advance pluripotent cell-based therapies from early development toward clinical and commercial manufacturing.
Under the agreement, RoslinCT will provide prospective customers with access to matched research-grade samples of BlueRock’s cell lines, while BlueRock will maintain oversight of commercial licensing.
RoslinCT and BlueRock have completed a technical transfer of the cell lines to RoslinCT’s facilities and team. RoslinCT said the transfer will allow it to support customers with services including cell banking, process and analytical development, and the manufacture of drug products for clinical and commercial use.
“Pluripotent cell-based therapies are increasingly advancing in the clinic and show promise for cost-effective therapies for a broad range of conditions. We are pleased to partner with BlueRock to further strengthen RoslinCT’s pluripotent cell therapy offering. By adding access to BlueRock’s clinical-grade lines alongside our own cell lines and development and manufacturing capabilities, we can provide customers with a more comprehensive pathway to support the development of advanced therapies from early-stage evaluation through to clinical and commercial supply,” said Peter Coleman, chief executive officer of RoslinCT.
“At BlueRock, we have invested significantly in developing clinical-grade pluripotent stem cell capabilities to support our own therapeutic programs,” said Greg Motz, vice president of research at BlueRock Therapeutics. “We are pleased to make these cell lines available through RoslinCT, helping provide cell therapy companies with additional resources to advance their therapies toward the clinic.”
RoslinCT said it supports cell therapy developers with capabilities spanning process and analytical development, cell banking, gene editing, differentiation, GMP manufacturing and commercial supply across autologous, allogeneic and pluripotent cell therapy platforms.
